Lexicon Pharmaceuticals, Inc.
LXRX
$1.88
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 284.16% | -61.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 284.16% | -61.27% | |||
| Cost of Revenue | 129.70% | -330.81% | |||
| Gross Profit | -83.12% | 1,164.54% | |||
| SG&A Expenses | 5.45% | 15.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.00% | -23.12% | |||
| Operating Income | 93.26% | -21.28% | |||
| Income Before Tax | 93.28% | -21.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 93.28% | -21.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 93.28% | -21.62% | |||
| EBIT | 93.26% | -21.28% | |||
| EBITDA | 93.96% | -21.82% | |||
| EPS Basic | 93.91% | -21.65% | |||
| Normalized Basic EPS | 94.01% | -21.36% | |||
| EPS Diluted | 93.91% | -21.65% | |||
| Normalized Diluted EPS | 94.01% | -21.36% | |||
| Average Basic Shares Outstanding | 10.13% | 0.01% | |||
| Average Diluted Shares Outstanding | 10.13% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||